Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.43 |
| ▸ | TNKS | O95271 | 9/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6646094 | 0.82 | TNKS (0.50) | PARP1TNKSTNKS2 | |
| SCHEMBL6645603 | 0.82 | KDM4E (0.45) | PARP1TNKSHTR3A | |
| SCHEMBL6644531 | 0.80 | PARP1 (0.44) | PARP1TNKS | |
| SCHEMBL6645162 | 0.80 | PARP1 (0.46) | PARP1TNKS | |
| SCHEMBL3442265 | 0.79 | TNKS (0.46) | PARP1TNKSTNKS2BRD4ATAD2 | |
| SCHEMBL6645436 | 0.78 | PARP1 (0.44) | PARP1TNKSTNKS2 | |
| Hydrochloric Acid SCHEMBL3442524 | 0.77 | HTR2C (0.47) | PARP1TNKSTNKS2BRD4ATAD2 | |
| SCHEMBL6642750 | 0.77 | PARP1 (0.43) | PARP1TNKSTNKS2 | |
| SCHEMBL3443155 | 0.76 | PARP14 (0.44) | PARP1TNKSBRD4ATAD2 | |
| SCHEMBL6647500 | 0.76 | TNKS (0.46) | PARP1TNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | claimed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | claimed |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | PARP11, PARP1, CD38 | PARP1 2/4885TNKS 121/4885TNKS2 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.